- 全部删除
- 您的购物车当前为空
CPI-637 是一种选择性和细胞活性的苯二氮卓 CBP/EP300 溴结构域抑制剂,其对 CBP、EP300和 BRD4 BD-1的 IC50值分别为 0.03、0.051 和 11.0 μM,对 CBP 的 EC50值为 0.3 μM。
为众多的药物研发团队赋能,
让新药发现更简单!
CPI-637 是一种选择性和细胞活性的苯二氮卓 CBP/EP300 溴结构域抑制剂,其对 CBP、EP300和 BRD4 BD-1的 IC50值分别为 0.03、0.051 和 11.0 μM,对 CBP 的 EC50值为 0.3 μM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 283 | In stock | |
2 mg | ¥ 395 | In stock | |
5 mg | ¥ 647 | In stock | |
10 mg | ¥ 913 | In stock | |
25 mg | ¥ 1,770 | In stock | |
50 mg | ¥ 3,230 | In stock | |
100 mg | ¥ 4,780 | In stock | |
500 mg | ¥ 9,870 | In stock |
CPI-637 相关产品
产品描述 | CPI-637 is a selective and cell-active benzodiazepinone CBP/EP300 bromodomain inhibitor. |
靶点活性 | BRD4 BD1:11 μM, CBP:0.03 μM, EP300:0.051 μM |
体外活性 | CPI-637 inhibits MYC expression in AMO-1 cells (EC50=0.60 μM)[1]. |
激酶实验 | Ki Determination: Inhibition of human full-length recombinant PARP-1 by [32P]NAD+ incorporation is measured. The [32P]ADP-ribose incorporated into acid insoluble material is quantified using a PhosphorImager. Ki is calculated by nonlinear regression analysis. |
细胞实验 | AMO-1 cells (DSMZ) were plated at 20,000 cells/well in 96-well plates in Iscove's Modified Dulbecco's Medium supplemented with 10% fetal calf serum. Cells were treated for 6 h with a dose titration of CPI-637 starting from a 5 μM top concentration. After 6 h, cells were lysed and processed for QuantiGene Plex expression analysis and data were collected on a MAGPIX multiplex Luminex instrument.(Only for Reference) |
别名 | CPI 637 |
分子量 | 386.45 |
分子式 | C22H22N6O |
CAS No. | 1884712-47-3 |
Smiles | C[C@@H]1CC(=O)Nc2cccc(-c3ccc4n(C)nc(-c5cnn(C)c5)c4c3)c2N1 |
密度 | 1.38 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
溶解度信息 | DMSO: 3.87 mg/mL (10 mM), Sonication is recommended. ![]() Ethanol: < 1 mg/mL (insoluble or slightly soluble) H2O: < 1 mg/mL (insoluble or slightly soluble) | ||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||
DMSO
|
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容